{"transactions":[{"id":2027006,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Integration Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:35:55.000Z","date":"2023-02-08","kind":"sale","acquired":false,"shares":701,"price":103.8296,"value":72784.5496,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Sale of 701 shares of common stock issued upon vesting of 1,328 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (627) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.58 to $105.72. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":42337,"source":{"system":"sec-edgar","filing":"0001209191-23-007914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007914/doc4.xml","form_type":"4"}},{"id":2027005,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Integration Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:35:55.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":12801,"price":102.4108,"value":1310960.6508,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 12,801 shares of common stock issued upon vesting of 24,298 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (11,497) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F6","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.08 to $103.84. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":41710,"source":{"system":"sec-edgar","filing":"0001209191-23-007914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007914/doc4.xml","form_type":"4"}},{"id":2027004,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Integration Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:35:55.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":1015,"price":102.1609,"value":103693.3135,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 1,015 shares of common stock issued upon vesting of 1,928 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (913) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.77 to $103.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30213,"source":{"system":"sec-edgar","filing":"0001209191-23-007914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007914/doc4.xml","form_type":"4"}},{"id":2027003,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Integration Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:35:55.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":801,"price":105.8153,"value":84758.0553,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 801 shares of common stock issued upon vesting of 1,519 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (718) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.03 to $106.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29300,"source":{"system":"sec-edgar","filing":"0001209191-23-007914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007914/doc4.xml","form_type":"4"}},{"id":2037156,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Integration Officer"}}],"security":"Common Stock","published_at":"2023-02-02T22:24:17.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":1666,"price":110.0183,"value":183290.4878,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,666 shares of common stock issued upon vesting of 3,164 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,498) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28582,"source":{"system":"sec-edgar","filing":"0001209191-23-006280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123006280/doc4.xml","form_type":"4"}},{"id":2184818,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Incentive Stock Option","published_at":"2022-08-16T22:44:11.000Z","date":"2022-08-15","kind":"exercise","acquired":false,"shares":1227,"price":81.49,"value":99988.23,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Option granted February 05, 2018 and vested monthly over four years"}],"balance_after":0,"derivative":{"exercise_price":81.49,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":1227},"source":{"system":"sec-edgar","filing":"0001209191-22-046070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122046070/doc4.xml","form_type":"4"}},{"id":2184817,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Incentive Stock Option","published_at":"2022-08-16T22:44:11.000Z","date":"2022-08-15","kind":"exercise","acquired":false,"shares":3361,"price":43.24,"value":145329.64,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Option granted February 06, 2017 and vested monthly over four years"}],"balance_after":0,"derivative":{"exercise_price":43.24,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":3361},"source":{"system":"sec-edgar","filing":"0001209191-22-046070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122046070/doc4.xml","form_type":"4"}},{"id":2184816,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Incentive Stock Option","published_at":"2022-08-16T22:44:11.000Z","date":"2022-08-15","kind":"exercise","acquired":false,"shares":3455,"price":35.99,"value":124345.45,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 05, 2016 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":3455},"source":{"system":"sec-edgar","filing":"0001209191-22-046070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122046070/doc4.xml","form_type":"4"}},{"id":2184815,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2022-08-16T22:44:11.000Z","date":"2022-08-12","kind":"exercise","acquired":false,"shares":21533,"price":35.99,"value":774972.67,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 05, 2016 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":21533},"source":{"system":"sec-edgar","filing":"0001209191-22-046070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122046070/doc4.xml","form_type":"4"}},{"id":2184814,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2022-08-16T22:44:11.000Z","date":"2022-08-15","kind":"exercise","acquired":true,"shares":1227,"price":81.49,"value":99988.23,"ownership":{"direct":true},"balance_after":26931,"source":{"system":"sec-edgar","filing":"0001209191-22-046070","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122046070/doc4.xml","form_type":"4"}},{"id":2184813,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2022-08-16T22:44:11.000Z","date":"2022-08-15","kind":"exercise","acquired":true,"shares":3361,"price":43.24,"value":145329.64,"ownership":{"direct":true},"balance_after":25704,"source":{"system":"sec-edgar","filing":"0001209191-22-046070","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122046070/doc4.xml","form_type":"4"}},{"id":2184812,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2022-08-16T22:44:11.000Z","date":"2022-08-15","kind":"exercise","acquired":true,"shares":3455,"price":35.99,"value":124345.45,"ownership":{"direct":true},"balance_after":22343,"source":{"system":"sec-edgar","filing":"0001209191-22-046070","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122046070/doc4.xml","form_type":"4"}},{"id":2184811,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2022-08-16T22:44:11.000Z","date":"2022-08-12","kind":"sale","acquired":false,"shares":21533,"price":105.9458,"value":2281330.9114,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.28 to $106.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 157 shares purchased on February 28, 2022 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":18888,"source":{"system":"sec-edgar","filing":"0001209191-22-046070","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122046070/doc4.xml","form_type":"4"}},{"id":2184810,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2022-08-16T22:44:11.000Z","date":"2022-08-12","kind":"exercise","acquired":true,"shares":21533,"price":35.99,"value":774972.67,"ownership":{"direct":true},"balance_after":40421,"source":{"system":"sec-edgar","filing":"0001209191-22-046070","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122046070/doc4.xml","form_type":"4"}},{"id":2406983,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2022-02-10T00:04:34.000Z","date":"2022-02-08","kind":"sale","acquired":false,"shares":701,"price":79.5301,"value":55750.6001,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Sale of 701 shares of common stock issued upon vesting of 1,328 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (627) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.10 to $79.92. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":18731,"source":{"system":"sec-edgar","filing":"0001209191-22-008214","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008214/doc4.xml","form_type":"4"}},{"id":2406982,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2022-02-10T00:04:34.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":801,"price":80.651,"value":64601.451,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 801 shares of common stock issued upon vesting of 1,518 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (717) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.77 to $81.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":18104,"source":{"system":"sec-edgar","filing":"0001209191-22-008214","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008214/doc4.xml","form_type":"4"}},{"id":2406981,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2022-02-10T00:04:34.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":1015,"price":80.729,"value":81939.935,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 1,015 shares of common stock issued upon vesting of 1,928 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (913) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.77 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":17387,"source":{"system":"sec-edgar","filing":"0001209191-22-008214","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008214/doc4.xml","form_type":"4"}},{"id":2406980,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2022-02-10T00:04:34.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":865,"price":80.7814,"value":69875.911,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 865 shares of common stock issued upon vesting of 1,538 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (673) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.99 to $81.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":16474,"source":{"system":"sec-edgar","filing":"0001209191-22-008214","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008214/doc4.xml","form_type":"4"}},{"id":2417573,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-02-03T01:08:51.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":3164,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units vests in full on the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units vests in full on the first anniversary of the date of grant."}],"balance_after":3164,"derivative":{"underlying":"Common Stock","underlying_shares":3164},"source":{"system":"sec-edgar","filing":"0001209191-22-006595","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122006595/doc4.xml","form_type":"4"}},{"id":2417572,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Option","published_at":"2022-02-03T01:08:51.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":21546,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/12th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":21546,"derivative":{"exercise_price":79.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":21546},"source":{"system":"sec-edgar","filing":"0001209191-22-006595","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122006595/doc4.xml","form_type":"4"}},{"id":2622510,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-07-29T21:32:39.000Z","date":"2021-07-27","kind":"sale","acquired":false,"shares":16709,"price":93.8019,"value":1567335.9471,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $93.13 to $95.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15801,"source":{"system":"sec-edgar","filing":"0001209191-21-048560","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121048560/doc4.xml","form_type":"4"}},{"id":2769850,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Option","published_at":"2021-03-29T10:23:37.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":35035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":35035,"derivative":{"exercise_price":117.63,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":35035},"source":{"system":"sec-edgar","filing":"0001209191-21-023385","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121023385/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-09"}},{"id":2864458,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2021-02-13T01:27:14.000Z","date":"2021-02-10","kind":"exercise","acquired":false,"shares":1700,"price":35.99,"value":61183.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 05, 2016 and vested monthly over four years."}],"balance_after":21533,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":1700},"source":{"system":"sec-edgar","filing":"0001209191-21-010498","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121010498/doc4.xml","form_type":"4"}},{"id":2864457,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-02-13T01:27:14.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":600,"price":119.9542,"value":71972.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $119.95 to $119.9650. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32510,"source":{"system":"sec-edgar","filing":"0001209191-21-010498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121010498/doc4.xml","form_type":"4"}},{"id":2864456,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-02-13T01:27:14.000Z","date":"2021-02-10","kind":"exercise","acquired":true,"shares":600,"price":35.99,"value":21594.0,"ownership":{"direct":true},"balance_after":33110,"source":{"system":"sec-edgar","filing":"0001209191-21-010498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121010498/doc4.xml","form_type":"4"}},{"id":2864455,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-02-13T01:27:14.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":1100,"price":119.9573,"value":131953.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $119.95 to $119.97. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32510,"source":{"system":"sec-edgar","filing":"0001209191-21-010498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121010498/doc4.xml","form_type":"4"}},{"id":2864454,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-02-13T01:27:14.000Z","date":"2021-02-10","kind":"exercise","acquired":true,"shares":1100,"price":35.99,"value":39589.0,"ownership":{"direct":true},"balance_after":33610,"source":{"system":"sec-edgar","filing":"0001209191-21-010498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121010498/doc4.xml","form_type":"4"}},{"id":2872951,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Restricted Stock Unit","published_at":"2021-02-10T02:20:23.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":5314,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025."}],"balance_after":5314,"derivative":{"underlying":"Common Stock","underlying_shares":5314},"source":{"system":"sec-edgar","filing":"0001209191-21-009121","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009121/doc4.xml","form_type":"4"}},{"id":2872950,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Option","published_at":"2021-02-10T02:20:23.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":31880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":31880,"derivative":{"exercise_price":117.63,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":31880},"source":{"system":"sec-edgar","filing":"0001209191-21-009121","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009121/doc4.xml","form_type":"4"}},{"id":2872949,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:20:23.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":1015,"price":116.8714,"value":118624.471,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Sale of 1,015 shares of common stock issued upon vesting of 1,928 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (913) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32510,"source":{"system":"sec-edgar","filing":"0001209191-21-009121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009121/doc4.xml","form_type":"4"}},{"id":2872948,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:20:23.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":1490,"price":116.7354,"value":173935.746,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 1,490 shares of common stock issued upon vesting of 2,650 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,160) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.99 to $117.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31597,"source":{"system":"sec-edgar","filing":"0001209191-21-009121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009121/doc4.xml","form_type":"4"}},{"id":2872947,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:20:23.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":756,"price":116.8902,"value":88368.9912,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 756 shares of common stock issued upon vesting of 1,518 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (762) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.91 to $117.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30437,"source":{"system":"sec-edgar","filing":"0001209191-21-009121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009121/doc4.xml","form_type":"4"}},{"id":2872946,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:20:23.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":865,"price":114.1494,"value":98739.231,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 865 shares of common stock issued upon vesting of 1,538 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (673) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.47 to $116.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29675,"source":{"system":"sec-edgar","filing":"0001209191-21-009121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009121/doc4.xml","form_type":"4"}},{"id":2893982,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2021-01-28T02:30:34.000Z","date":"2021-01-26","kind":"exercise","acquired":false,"shares":1100,"price":35.99,"value":39589.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 05, 2016 and vested monthly over four years."}],"balance_after":23233,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0001209191-21-005820","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005820/doc4.xml","form_type":"4"}},{"id":2893981,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2021-01-28T02:30:34.000Z","date":"2021-01-25","kind":"exercise","acquired":false,"shares":8958,"price":32.99,"value":295524.42,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Option granted February 03, 2015 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":8958},"source":{"system":"sec-edgar","filing":"0001209191-21-005820","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005820/doc4.xml","form_type":"4"}},{"id":2893980,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2021-01-28T02:30:34.000Z","date":"2021-01-25","kind":"exercise","acquired":false,"shares":8612,"price":35.99,"value":309945.88,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 05, 2016 and vested monthly over four years."}],"balance_after":24333,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":8612},"source":{"system":"sec-edgar","filing":"0001209191-21-005820","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005820/doc4.xml","form_type":"4"}},{"id":2893979,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-01-28T02:30:34.000Z","date":"2021-01-26","kind":"sale","acquired":false,"shares":600,"price":119.9758,"value":71985.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $119.96 to $120.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29002,"source":{"system":"sec-edgar","filing":"0001209191-21-005820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005820/doc4.xml","form_type":"4"}},{"id":2893978,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-01-28T02:30:34.000Z","date":"2021-01-26","kind":"exercise","acquired":true,"shares":600,"price":35.99,"value":21594.0,"ownership":{"direct":true},"balance_after":29602,"source":{"system":"sec-edgar","filing":"0001209191-21-005820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005820/doc4.xml","form_type":"4"}},{"id":2893977,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-01-28T02:30:34.000Z","date":"2021-01-26","kind":"sale","acquired":false,"shares":500,"price":119.96,"value":59980.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":29002,"source":{"system":"sec-edgar","filing":"0001209191-21-005820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005820/doc4.xml","form_type":"4"}},{"id":2893976,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-01-28T02:30:34.000Z","date":"2021-01-26","kind":"exercise","acquired":true,"shares":500,"price":35.99,"value":17995.0,"ownership":{"direct":true},"balance_after":29502,"source":{"system":"sec-edgar","filing":"0001209191-21-005820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005820/doc4.xml","form_type":"4"}},{"id":2893975,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-01-28T02:30:34.000Z","date":"2021-01-25","kind":"sale","acquired":false,"shares":8958,"price":119.95,"value":1074512.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":29002,"source":{"system":"sec-edgar","filing":"0001209191-21-005820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005820/doc4.xml","form_type":"4"}},{"id":2893974,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-01-28T02:30:34.000Z","date":"2021-01-25","kind":"exercise","acquired":true,"shares":8958,"price":32.99,"value":295524.42,"ownership":{"direct":true},"balance_after":37960,"source":{"system":"sec-edgar","filing":"0001209191-21-005820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005820/doc4.xml","form_type":"4"}},{"id":2893973,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-01-28T02:30:34.000Z","date":"2021-01-25","kind":"sale","acquired":false,"shares":4601,"price":119.9828,"value":552040.8628,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $119.95 to $120.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29002,"source":{"system":"sec-edgar","filing":"0001209191-21-005820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005820/doc4.xml","form_type":"4"}},{"id":2893972,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-01-28T02:30:34.000Z","date":"2021-01-25","kind":"exercise","acquired":true,"shares":4601,"price":35.99,"value":165589.99,"ownership":{"direct":true},"balance_after":33603,"source":{"system":"sec-edgar","filing":"0001209191-21-005820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005820/doc4.xml","form_type":"4"}},{"id":2893971,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-01-28T02:30:34.000Z","date":"2021-01-25","kind":"sale","acquired":false,"shares":4011,"price":119.9848,"value":481259.0328,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $119.95 to $120.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29002,"source":{"system":"sec-edgar","filing":"0001209191-21-005820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005820/doc4.xml","form_type":"4"}},{"id":2893970,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2021-01-28T02:30:34.000Z","date":"2021-01-25","kind":"exercise","acquired":true,"shares":4011,"price":35.99,"value":144355.89,"ownership":{"direct":true},"balance_after":33013,"source":{"system":"sec-edgar","filing":"0001209191-21-005820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121005820/doc4.xml","form_type":"4"}},{"id":2980250,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2020-11-16T23:21:47.000Z","date":"2020-11-12","kind":"sale","acquired":false,"shares":2257,"price":90.7292,"value":204775.8044,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,257 shares of common stock issued upon vesting of 4,288 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,031) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $88.93 to $92.23. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29002,"source":{"system":"sec-edgar","filing":"0001209191-20-058551","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120058551/doc4.xml","form_type":"4"}},{"id":3065177,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2020-08-07T23:47:43.000Z","date":"2020-08-05","kind":"sale","acquired":false,"shares":2257,"price":118.8646,"value":268277.4022,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,257 shares of common stock issued upon vesting of 4,287 performance restricted stock units to cover withholding\ntaxes, with the balance of the shares (2,030) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a\nbroker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction\ndate in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan\nsubsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.21 to $120.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":26971,"source":{"system":"sec-edgar","filing":"0001209191-20-045767","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120045767/doc4.xml","form_type":"4"}},{"id":3168580,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2020-04-29T00:44:05.000Z","date":"2020-04-24","kind":"sale","acquired":false,"shares":1934,"price":99.4463,"value":192329.1442,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.59 to $101.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24941,"source":{"system":"sec-edgar","filing":"0001209191-20-026071","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120026071/doc4.xml","form_type":"4"}},{"id":3280529,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2020-02-12T00:21:10.000Z","date":"2020-02-10","kind":"exercise","acquired":false,"shares":15927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Option granted February 5, 2018 and vests monthly over four years."}],"balance_after":17596,"derivative":{"exercise_price":81.49,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":15927},"source":{"system":"sec-edgar","filing":"0001209191-20-008513","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120008513/doc4.xml","form_type":"4"}},{"id":3280528,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Incentive Stock Option","published_at":"2020-02-12T00:21:10.000Z","date":"2020-02-10","kind":"exercise","acquired":false,"shares":13042,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Option granted February 3, 2015 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":13042},"source":{"system":"sec-edgar","filing":"0001209191-20-008513","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120008513/doc4.xml","form_type":"4"}},{"id":3280527,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2020-02-12T00:21:10.000Z","date":"2020-02-10","kind":"sale","acquired":false,"shares":15927,"price":104.563,"value":1665374.901,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.56 to $105.08. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23200,"source":{"system":"sec-edgar","filing":"0001209191-20-008513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120008513/doc4.xml","form_type":"4"}},{"id":3280526,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2020-02-12T00:21:10.000Z","date":"2020-02-10","kind":"exercise","acquired":true,"shares":15927,"price":81.49,"value":1297891.23,"ownership":{"direct":true},"balance_after":39127,"source":{"system":"sec-edgar","filing":"0001209191-20-008513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120008513/doc4.xml","form_type":"4"}},{"id":3280525,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2020-02-12T00:21:10.000Z","date":"2020-02-10","kind":"sale","acquired":false,"shares":13042,"price":104.563,"value":1363710.646,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.00 to $104.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23200,"source":{"system":"sec-edgar","filing":"0001209191-20-008513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120008513/doc4.xml","form_type":"4"}},{"id":3280524,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2020-02-12T00:21:10.000Z","date":"2020-02-10","kind":"exercise","acquired":true,"shares":13042,"price":32.99,"value":430255.58,"ownership":{"direct":true},"balance_after":36242,"source":{"system":"sec-edgar","filing":"0001209191-20-008513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120008513/doc4.xml","form_type":"4"}},{"id":3280523,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2020-02-12T00:21:10.000Z","date":"2020-02-07","kind":"sale","acquired":false,"shares":1015,"price":103.2774,"value":104826.561,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,015 shares of common stock issued upon vesting of 1,928 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (913) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.24 to $104.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23200,"source":{"system":"sec-edgar","filing":"0001209191-20-008513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120008513/doc4.xml","form_type":"4"}},{"id":3285289,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Restricted Stock Unit","published_at":"2020-02-07T23:47:09.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":6074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024."}],"balance_after":6074,"derivative":{"underlying":"Common Stock","underlying_shares":6074},"source":{"system":"sec-edgar","filing":"0001209191-20-007686","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007686/doc4.xml","form_type":"4"}},{"id":3285288,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Option","published_at":"2020-02-07T23:47:09.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":38342,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":38342,"derivative":{"exercise_price":102.9,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":38342},"source":{"system":"sec-edgar","filing":"0001209191-20-007686","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007686/doc4.xml","form_type":"4"}},{"id":3285287,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2020-02-07T23:47:09.000Z","date":"2020-02-06","kind":"sale","acquired":false,"shares":1490,"price":101.5154,"value":151257.946,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 1,490 shares of common stock issued upon vesting of 2,650 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,160) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.12 to $103.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22287,"source":{"system":"sec-edgar","filing":"0001209191-20-007686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007686/doc4.xml","form_type":"4"}},{"id":3285286,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2020-02-07T23:47:09.000Z","date":"2020-02-05","kind":"sale","acquired":false,"shares":865,"price":103.0595,"value":89146.4675,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 865 shares of common stock issued upon vesting of 1,537 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (672) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $105.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21127,"source":{"system":"sec-edgar","filing":"0001209191-20-007686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007686/doc4.xml","form_type":"4"}},{"id":3285285,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2020-02-07T23:47:09.000Z","date":"2020-02-05","kind":"sale","acquired":false,"shares":1083,"price":103.0345,"value":111586.3635,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,083 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (842) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $105.04. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":20455,"source":{"system":"sec-edgar","filing":"0001209191-20-007686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007686/doc4.xml","form_type":"4"}},{"id":3393203,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-10-16T20:20:23.000Z","date":"2019-10-14","kind":"exercise","acquired":false,"shares":9956,"price":15.45,"value":153820.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted October 1, 2014 and vested at 25% upon first anniversary (October 1, 2015) and remaining 75% vested in 36 equal monthly installments beginning November 1, 2015."}],"balance_after":0,"derivative":{"exercise_price":15.45,"expiration_date":"2024-10-01","underlying":"Common Stock","underlying_shares":9956},"source":{"system":"sec-edgar","filing":"0001209191-19-053286","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119053286/doc4.xml","form_type":"4"}},{"id":3393202,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2019-10-16T20:20:23.000Z","date":"2019-10-14","kind":"sale","acquired":false,"shares":9956,"price":90.8484,"value":904486.6704,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $90.05 to $91.70 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":19613,"source":{"system":"sec-edgar","filing":"0001209191-19-053286","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119053286/doc4.xml","form_type":"4"}},{"id":3393201,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2019-10-16T20:20:23.000Z","date":"2019-10-14","kind":"exercise","acquired":true,"shares":9956,"price":15.45,"value":153820.2,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes a total of 375 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan. 190 shares were purchased on February 28, 2019 and 185 shares were purchased on August 30, 2019."}],"balance_after":29569,"source":{"system":"sec-edgar","filing":"0001209191-19-053286","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119053286/doc4.xml","form_type":"4"}},{"id":3669090,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Restricted Stock Unit","published_at":"2019-02-08T22:11:30.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":7712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023."}],"balance_after":7712,"derivative":{"underlying":"Common Stock","underlying_shares":7712},"source":{"system":"sec-edgar","filing":"0001209191-19-008643","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119008643/doc4.xml","form_type":"4"}},{"id":3669089,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Option","published_at":"2019-02-08T22:11:30.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":41671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter."}],"balance_after":41671,"derivative":{"exercise_price":81.05,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":41671},"source":{"system":"sec-edgar","filing":"0001209191-19-008643","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119008643/doc4.xml","form_type":"4"}},{"id":3669088,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2019-02-08T22:11:30.000Z","date":"2019-02-06","kind":"sale","acquired":false,"shares":920,"price":83.5802,"value":76893.784,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 920 shares of common stock issued upon vesting of 2,650 restricted stock units on February 6, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,730) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.80 to $84.9646. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":19238,"source":{"system":"sec-edgar","filing":"0001209191-19-008643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119008643/doc4.xml","form_type":"4"}},{"id":3672758,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2019-02-06T23:06:03.000Z","date":"2019-02-05","kind":"sale","acquired":false,"shares":603,"price":88.1306,"value":53142.7518,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 603 shares of common stock issued upon vesting of 1,537 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (934) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.48 to $88.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":17508,"source":{"system":"sec-edgar","filing":"0001209191-19-007854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119007854/doc4.xml","form_type":"4"}},{"id":3672757,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2019-02-06T23:06:03.000Z","date":"2019-02-05","kind":"sale","acquired":false,"shares":669,"price":88.1552,"value":58975.8288,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 669 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,256) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.27 to $88.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":16574,"source":{"system":"sec-edgar","filing":"0001209191-19-007854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119007854/doc4.xml","form_type":"4"}},{"id":3770932,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-11-08T22:03:24.000Z","date":"2018-11-07","kind":"exercise","acquired":true,"shares":3300,"price":15.45,"value":50985.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option granted October 1, 2014 and vested 25% upon first anniversary (October 1, 2015) and remaining 75% vested in 36 equal monthly installments beginning November 1, 2015."}],"balance_after":9956,"derivative":{"exercise_price":15.45,"expiration_date":"2024-10-01","underlying":"Common Stock","underlying_shares":3300},"source":{"system":"sec-edgar","filing":"0001209191-18-057771","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057771/doc4.xml","form_type":"4"}},{"id":3770931,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-11-08T22:03:24.000Z","date":"2018-11-06","kind":"exercise","acquired":true,"shares":5700,"price":15.45,"value":88065.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option granted October 1, 2014 and vested 25% upon first anniversary (October 1, 2015) and remaining 75% vested in 36 equal monthly installments beginning November 1, 2015."}],"balance_after":13256,"derivative":{"exercise_price":15.45,"expiration_date":"2024-10-01","underlying":"Common Stock","underlying_shares":5700},"source":{"system":"sec-edgar","filing":"0001209191-18-057771","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057771/doc4.xml","form_type":"4"}},{"id":3770930,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2018-11-08T22:03:24.000Z","date":"2018-11-07","kind":"sale","acquired":false,"shares":3300,"price":110,"value":363000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":15318,"source":{"system":"sec-edgar","filing":"0001209191-18-057771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057771/doc4.xml","form_type":"4"}},{"id":3770929,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2018-11-08T22:03:24.000Z","date":"2018-11-07","kind":"exercise","acquired":true,"shares":3300,"price":15.45,"value":50985.0,"ownership":{"direct":true},"balance_after":18618,"source":{"system":"sec-edgar","filing":"0001209191-18-057771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057771/doc4.xml","form_type":"4"}},{"id":3770928,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2018-11-08T22:03:24.000Z","date":"2018-11-06","kind":"sale","acquired":false,"shares":5700,"price":110.0168,"value":627095.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":15318,"source":{"system":"sec-edgar","filing":"0001209191-18-057771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057771/doc4.xml","form_type":"4"}},{"id":3770927,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2018-11-08T22:03:24.000Z","date":"2018-11-06","kind":"exercise","acquired":true,"shares":5700,"price":15.45,"value":88065.0,"ownership":{"direct":true},"balance_after":21018,"source":{"system":"sec-edgar","filing":"0001209191-18-057771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057771/doc4.xml","form_type":"4"}},{"id":4072715,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Restricted Stock Unit","published_at":"2018-02-07T23:07:52.000Z","date":"2018-02-05","kind":"grant","acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period."}],"balance_after":12250,"derivative":{"expiration_date":"2021-03-15","underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0001209191-18-008217","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118008217/doc4.xml","form_type":"4"}},{"id":4072714,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Restricted Stock Unit","published_at":"2018-02-07T23:07:52.000Z","date":"2018-02-05","kind":"grant","acquired":true,"shares":6150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022."}],"balance_after":6150,"derivative":{"underlying":"Common Stock","underlying_shares":6150},"source":{"system":"sec-edgar","filing":"0001209191-18-008217","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118008217/doc4.xml","form_type":"4"}},{"id":4072713,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Options","published_at":"2018-02-07T23:07:52.000Z","date":"2018-02-05","kind":"grant","acquired":true,"shares":34750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 5, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter."}],"balance_after":34750,"derivative":{"exercise_price":81.49,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":34750},"source":{"system":"sec-edgar","filing":"0001209191-18-008217","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118008217/doc4.xml","form_type":"4"}},{"id":4072712,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2018-02-07T23:07:52.000Z","date":"2018-02-06","kind":"tax_withholding","acquired":false,"shares":1314,"price":82.48,"value":108378.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Payment of tax liability by withholding 1,314 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,336) maintained by the Reporting Person."}],"balance_after":15318,"source":{"system":"sec-edgar","filing":"0001209191-18-008217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118008217/doc4.xml","form_type":"4"}},{"id":4072711,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2018-02-07T23:07:52.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":960,"price":83.1902,"value":79862.592,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 960 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (965) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in\na Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the\nReporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":13982,"source":{"system":"sec-edgar","filing":"0001209191-18-008217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118008217/doc4.xml","form_type":"4"}},{"id":4108802,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-01-04T21:05:40.000Z","date":"2018-01-02","kind":"exercise","acquired":false,"shares":18084,"price":15.45,"value":279397.8,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option which vests 1/4 upon anniversary of grant (10/1/2015), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 10/1/2018."}],"balance_after":18956,"derivative":{"exercise_price":15.45,"expiration_date":"2024-10-01","underlying":"Common Stock","underlying_shares":18084},"source":{"system":"sec-edgar","filing":"0001209191-18-001889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118001889/doc4.xml","form_type":"4"}},{"id":4108801,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2018-01-04T21:05:40.000Z","date":"2018-01-02","kind":"sale","acquired":false,"shares":18084,"price":77.5173,"value":1401822.8532,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $76.00 to $79.93. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":13017,"source":{"system":"sec-edgar","filing":"0001209191-18-001889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118001889/doc4.xml","form_type":"4"}},{"id":4108800,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2018-01-04T21:05:40.000Z","date":"2018-01-02","kind":"exercise","acquired":true,"shares":18084,"price":15.45,"value":279397.8,"ownership":{"direct":true},"balance_after":31101,"source":{"system":"sec-edgar","filing":"0001209191-18-001889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118001889/doc4.xml","form_type":"4"}},{"id":4308876,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-05-23T20:34:42.000Z","date":"2017-05-19","kind":"exercise","acquired":false,"shares":4980,"price":15.45,"value":76941.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option which vests 1/4 upon anniversary of grant (10/1/2015), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 10/1/2018."}],"balance_after":37040,"derivative":{"exercise_price":15.45,"exercise_date":"2015-10-01","expiration_date":"2024-10-01","underlying":"Common Stock","underlying_shares":4980},"source":{"system":"sec-edgar","filing":"0001209191-17-034632","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117034632/doc4.xml","form_type":"4"}},{"id":4308875,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-05-23T20:34:42.000Z","date":"2017-05-18","kind":"exercise","acquired":false,"shares":4980,"price":15.45,"value":76941.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option which vests 1/4 upon anniversary of grant (10/1/2015), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 10/1/2018."}],"balance_after":42020,"derivative":{"exercise_price":15.45,"exercise_date":"2015-10-01","expiration_date":"2024-10-01","underlying":"Common Stock","underlying_shares":4980},"source":{"system":"sec-edgar","filing":"0001209191-17-034632","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117034632/doc4.xml","form_type":"4"}},{"id":4308874,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2017-05-23T20:34:42.000Z","date":"2017-05-19","kind":"sale","acquired":false,"shares":4980,"price":54,"value":268920.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":13017,"source":{"system":"sec-edgar","filing":"0001209191-17-034632","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117034632/doc4.xml","form_type":"4"}},{"id":4308873,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2017-05-23T20:34:42.000Z","date":"2017-05-19","kind":"exercise","acquired":true,"shares":4980,"price":15.45,"value":76941.0,"ownership":{"direct":true},"balance_after":17997,"source":{"system":"sec-edgar","filing":"0001209191-17-034632","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117034632/doc4.xml","form_type":"4"}},{"id":4308872,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2017-05-23T20:34:42.000Z","date":"2017-05-18","kind":"sale","acquired":false,"shares":4980,"price":53.26,"value":265234.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $52.53 to $53.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":13017,"source":{"system":"sec-edgar","filing":"0001209191-17-034632","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117034632/doc4.xml","form_type":"4"}},{"id":4308871,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2017-05-23T20:34:42.000Z","date":"2017-05-18","kind":"exercise","acquired":true,"shares":4980,"price":15.45,"value":76941.0,"ownership":{"direct":true},"balance_after":17997,"source":{"system":"sec-edgar","filing":"0001209191-17-034632","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117034632/doc4.xml","form_type":"4"}},{"id":4352930,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2017-04-13T20:56:04.000Z","date":"2017-04-12","kind":"sale","acquired":false,"shares":204,"price":51.23,"value":10450.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 13,065 shares of common stock issued upon vesting of 25,000 performance restricted stock units on April 11, 2017 to cover withholding taxes, with the balance of the shares (11,935) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $51.19 to $51.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":13017,"source":{"system":"sec-edgar","filing":"0001209191-17-026883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117026883/doc4.xml","form_type":"4"}},{"id":4352929,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2017-04-13T20:56:04.000Z","date":"2017-04-12","kind":"sale","acquired":false,"shares":12861,"price":50.41,"value":648323.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 13,065 shares of common stock issued upon vesting of 25,000 performance restricted stock units on April 11, 2017 to cover withholding taxes, with the balance of the shares (11,935) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $50.20 to $50.73. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":13221,"source":{"system":"sec-edgar","filing":"0001209191-17-026883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117026883/doc4.xml","form_type":"4"}},{"id":4462333,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Restricted Stock Option","published_at":"2017-02-09T00:41:34.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":10600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021."}],"balance_after":10600,"derivative":{"underlying":"Common Stock","underlying_shares":10600},"source":{"system":"sec-edgar","filing":"0001209191-17-008913","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117008913/doc4.xml","form_type":"4"}},{"id":4462332,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Option","published_at":"2017-02-09T00:41:34.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":76800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter."}],"balance_after":76800,"derivative":{"exercise_price":43.24,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":76800},"source":{"system":"sec-edgar","filing":"0001209191-17-008913","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117008913/doc4.xml","form_type":"4"}},{"id":4462331,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2017-02-09T00:41:34.000Z","date":"2017-02-07","kind":"sale","acquired":false,"shares":116,"price":44.61,"value":5174.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 727 and 116 shares of common stock issued upon vesting of 1925 restricted stock units to cover withholding taxes with the balance of the shares (1082) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":1082,"source":{"system":"sec-edgar","filing":"0001209191-17-008913","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117008913/doc4.xml","form_type":"4"}},{"id":4462330,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":117153,"kind":"person","name":"Lloyd-Smith Malcolm","position":1,"cik":"0001557146","reported_name":"Lloyd-Smith Malcolm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2017-02-09T00:41:34.000Z","date":"2017-02-06","kind":"sale","acquired":false,"shares":727,"price":43.15,"value":31370.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 727 and 116 shares of common stock issued upon vesting of 1925 restricted stock units to cover withholding taxes with the balance of the shares (1082) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-008913","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117008913/doc4.xml","form_type":"4"}}]}